Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
Identifieur interne : 001080 ( Ncbi/Merge ); précédent : 001079; suivant : 001081Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
Auteurs : Ruklanthi De Alwis [Singapour] ; Shiwei Chen [Singapour] ; Esther S. Gan [Singapour] ; Eng Eong Ooi [Singapour]Source :
- EBioMedicine [ 2352-3964 ] ; 2020.
Abstract
The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
DOI: 10.1016/j.ebiom.2020.102768
PubMed: 32344202
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000021
- to stream PubMed, to step Curation: 000021
- to stream PubMed, to step Checkpoint: 000094
Links to Exploration step
pubmed:32344202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</title>
<author><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name>
<affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre</wicri:regionArea>
<wicri:noRegion>SingHealth Duke-NUS Academic Medical Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name>
<affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea>
<wicri:noRegion>Duke-NUS Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name>
<affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea>
<wicri:noRegion>Duke-NUS Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name>
<affiliation wicri:level="4"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea>
<orgName type="university">Université nationale de Singapour</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32344202</idno>
<idno type="pmid">32344202</idno>
<idno type="doi">10.1016/j.ebiom.2020.102768</idno>
<idno type="wicri:Area/PubMed/Corpus">000021</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000021</idno>
<idno type="wicri:Area/PubMed/Curation">000021</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000021</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000094</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000094</idno>
<idno type="wicri:Area/Ncbi/Merge">001080</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</title>
<author><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name>
<affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre</wicri:regionArea>
<wicri:noRegion>SingHealth Duke-NUS Academic Medical Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name>
<affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea>
<wicri:noRegion>Duke-NUS Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name>
<affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea>
<wicri:noRegion>Duke-NUS Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name>
<affiliation wicri:level="4"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea>
<orgName type="university">Université nationale de Singapour</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">EBioMedicine</title>
<idno type="eISSN">2352-3964</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32344202</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>55</Volume>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>EBioMedicine</Title>
<ISOAbbreviation>EBioMedicine</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</ArticleTitle>
<Pagination><MedlinePgn>102768</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30143-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.102768</ELocationID>
<Abstract><AbstractText>The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Alwis</LastName>
<ForeName>Ruklanthi</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Shiwei</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gan</LastName>
<ForeName>Esther S</ForeName>
<Initials>ES</Initials>
<AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ooi</LastName>
<ForeName>Eng Eong</ForeName>
<Initials>EE</Initials>
<AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>EBioMedicine</MedlineTA>
<NlmUniqueID>101647039</NlmUniqueID>
<ISSNLinking>2352-3964</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Polyclonal hyperimmune globulin</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">Vaccines</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32344202</ArticleId>
<ArticleId IdType="pii">S2352-3964(20)30143-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.ebiom.2020.102768</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Singapour</li>
</country>
<orgName><li>Université nationale de Singapour</li>
</orgName>
</list>
<tree><country name="Singapour"><noRegion><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name>
</noRegion>
<name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name>
<name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name>
<name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001080 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001080 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= StressCovidV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:32344202 |texte= Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32344202" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a StressCovidV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |